A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
about
In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-diseaseTreatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodiesCurrent and future approaches for control of graft-versus-host disease.Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).Emerging therapies for graft-versus-host disease.Options for T-cell based therapies.How I treat refractory acute GVHD.Rituximab for steroid-refractory chronic graft-versus-host disease.Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseT regulatory cells as an immunotherapy for transplantation.Update in the treatment of paediatric ulcerative colitis.Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.Treatment of inflammatory bowel disease: a review of medical therapy.Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodiesPrevention and treatment of acute GvHD.Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.How I treat EBV lymphoproliferation.Mesenchymal stem cells targeting the GVHD.Acute graft-versus-host disease: new treatment strategies.T-cell-directed therapies in inflammatory bowel diseases.Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Recent developments in the prevention and treatment of Epstein-Barr virus-associated lymphoproliferative diseases.T-cell therapy in the treatment of post-transplant lymphoproliferative diseaseImmune tolerance and transplantation.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Humanizing animal models: a key to autoimmune diabetes treatment.Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease.Euroconference on tissue repair and ulcer/wound healing: molecular mechanisms, therapeutic targets and future directions.Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.Immunogenicity screening in protein drug development.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.Limited role of charge matching in the interaction of human immunoglobulin A with the immunoglobulin A Fc receptor (Fc alpha RI) CD89.2nd International Conference on Immune-Mediated Diseases & 8th International Anti-Inflammation Meeting.Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
P2860
Q27307168-7C6FFE5C-7F3D-45AE-84FA-80E34A8CB969Q33213561-E1B84B78-63FB-4480-B4C2-744206D2D8B2Q33497983-DD2CE259-81CC-4AFB-9933-23F907A0EA50Q33637111-F130EAAD-F790-4742-8EB5-303B0FAC8346Q33642625-7404A84A-A06E-408F-A091-775BA9833F68Q34828735-EF24C139-A26E-4284-8A41-7FEA88A2AFB2Q35602633-C1B348B1-08C2-4F6F-A1D2-312A5795DFB6Q35813115-21C40878-0096-4BD8-87DF-34B94058F6CCQ35828633-32C9212D-8EC9-4EDE-9C4F-743D0ADE15DBQ35848933-B4F8EFFC-05C4-404F-B625-7F04CA1114B7Q36024673-0E0718A3-53AA-4637-B43D-C6169B6AA6BCQ36425917-CE771CD4-D3C9-409A-AF69-512A0C565098Q36613876-A721FD59-3EF5-4EBE-899A-EB442815BF65Q36904078-EEA8320F-B929-4D8A-9423-771FDD7E0548Q37058862-65616E93-A76B-4A79-8341-52A65A3842C8Q37106206-CAB66CFC-E709-40D5-9C7D-97B7D71F8BA3Q37188487-54968E34-8D84-4B6E-A400-DE04972F317EQ37331009-E184D3A3-12D1-4A57-BE2F-D400E8794EE9Q37414678-F0CCB220-527A-46FC-B95C-4DD786C2F2CBQ37566315-4101E274-5F7F-40FB-B07E-7B60A2514F78Q37610714-D5BBC7F9-D15A-4052-B4B9-00B7AB05397CQ37720783-3EFE13F4-72C6-4028-947E-BA0F821EF52EQ37739028-DD439688-6813-499C-A67A-2E657F680759Q37810286-B97CE1D8-2667-4A4E-B2E0-0DBD053A0D29Q37851519-6FB1778F-0874-43FC-9841-782DFD8FFDA7Q37906623-567C56E3-971C-4166-A70D-ACCBC2F3E95DQ38026758-F7765CAF-F5F7-4153-8B69-8728D2323EB0Q38064621-1B17D2D5-D201-49F3-B044-04AB34FCF10CQ38066586-6C570498-0A68-4F11-B941-5591EF2264EDQ38202541-84469B7B-71C0-498E-B3C0-6D3E44A1DD54Q42818772-97811A81-71C9-47EC-8C13-4A2D6AC28476Q43228479-488C588E-C426-442B-B425-30BCE9A37B8DQ43273885-8B4D6D3A-EF46-4695-9E3F-5153F2FC7922Q45138047-EEC93CAA-98B3-449B-A1AE-E0D1C56323F0Q45204126-8551A304-E086-4578-BD79-F595EF872C4DQ49168236-4AF5B319-D43A-4C44-B2B5-67AFC735EEFEQ50041876-CE4BF51C-7BC2-4E17-BF4C-57A1D59B1AD3Q51836277-AF820768-83C9-4195-B5DF-683FB45C3B4CQ53289288-4267CA7D-7217-4C40-9467-4F56CFDE1293Q53871783-AB3F612D-DD01-46B3-8369-CECB1501C277
P2860
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@ast
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@en
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@nl
type
label
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@ast
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@en
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@nl
prefLabel
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@ast
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@en
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@nl
P2093
P50
P356
P1433
P1476
A humanized non-FcR-binding an ...... ute graft-versus-host disease.
@en
P2093
Ann Woolfrey
Claudio Anasetti
Daniel Levitt
James Krueger
Jean Sanders
John Slattery
Kris Doney
Paul A Carpenter
Paul Martin
Sandra Pavlovic
P304
P356
10.1182/BLOOD.V99.8.2712
P407
P577
2002-04-01T00:00:00Z